clinical trial · NCT07662109
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Type 2 Diabetes MellitusElecoglipronDapagliflozinElecoglipron-matched placeboDapagliflozin-matched placebo
brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
started
Jul 6, 2026
primary completion
Jul 5, 2028
completion
Jul 5, 2028
last updated
Jul 15, 2026
official title
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol